Agoracom Blog Home

Posts Tagged ‘MMJ’

Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:57 AM on Thursday, November 1st, 2018

Logo tetrabiopharma rgb web

  • Announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
  • This represents the first ever human clinical trial featuring a vaporized cannabinoid drug product 

OTTAWA, Nov. 01, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.

This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain.   It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.

“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor.  This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need.  It may also provide an alternative mode of delivery for those patients who prefer not to smoke.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.  For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

VIDEO: Northbud $NBUD.ca October Construction Update $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:49 PM on Wednesday, October 31st, 2018

Northbud large

NORTHBUD October Construction Update. Everything is on schedule!

Hub On AGORACOM / Corporate Profile

Bougainville Ventures Inc. $BOG.ca Provides Corporate Update & Signs LOI with Oregon Hemp CBD Producer $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 2:06 PM on Monday, October 29th, 2018

681747 5720 copy 2

  • Signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing license issued by the Oregon State Regulatory approval board

Bougainville Ventures Inc. has signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing licence issued by the Oregon State Regulatory approval board. The material terms of the LOI are summarized below. LOI Terms

1. The parties shall enter into a funding and profit sharing agreement with both companies receiving dividends. The profit sharing percentages will be stipulated in the definitive agreement.

2. Bougainville will agree to issue to Worm Castings 600,000 shares of Bougainville Ventures Inc. for assets and goodwill of Worm Castings.

3. Bougainville will also agree to raise $350,000 USD to be used to fund Worm Castings’ business plan. The funds are expected to be provided on the following schedule:

a. $75,000 by November 7, 2018

b. $75,000 by November 30, 2018

c. $200,000 by December 31, 2018

4. Worm Castings will submit to Bougainville a complete list of assets to be included in the definitive agreement

About Worm Castings Farms Inc.

Worm Castings is a natural hemp company that currently has 10 acres of industrial hemp ready for harvest. They plant premium high quality cloned feminized hemp plants with 10-15% CBD and 0.3% THC resulting in maximized CBD oil content within each plant. In addition, they provide proven topsoil mix that improves plant growth by 20%. With this soil quality, they can expect to set standards in respective markets within the hemp industry.

CEO, Andy Jagpal Comments: “The objective of this project is to extract CBD oil from Hemp stock by providing the initial capital for the continued development of the 10 acre farmland and is a step in the right direction in diversifying our portfolio of companies in the cannabis infrastructure space .”

Oroville Campus Tier -3 Tenant Update

The Company also reports that it has recently become aware that Marijuana Company of America, Inc. (“MCOA”) has purportedly terminated its joint venture agreement with the Company dated March 16, 2017 (“JV Agreement”), and that it may have commenced legal action against the Company relating to various claims. The Company has not been served with a claim and has not receive a notice of default related to the JV agreement and will investigate this matter further. If subject to a claim, the Company intends to defend vigorously and to pursue all legal actions available to it. The Company notes that the JV Agreement relating to the acre of the 4.33 acre parcel of land located at Oroville Campus will continue for occupancy for its tenant.

Oroville Campus Tier -2 Tenant Update

The Company notes that the new I-502 Tier-2 licensee tenant and lease agreement relating to the 3.33 acre parcel of land in the Oroville Campus announced in the Company’s news release dated October 23, 2018 is not subject to the JV Agreement with MCOA and indeed resides on a separate parcel of land. Operations relating to such tenant are proceeding as previously announced.

About Bougainville Ventures, Inc.

Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sqft in near production in Oroville, WA.

We seek Safe Harbor.

#Marijuana shortages abound in Canada in just second week of legalization $BOG.ca NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:54 AM on Monday, October 29th, 2018

  • The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.
  • “We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

People check out the sample counter at a cannabis store in Winnipeg, Man., on Oct. 17.Canadian Press/John Woods

Kristine Owram

The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.

“We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

Every province, not just Manitoba, is receiving less cannabis than originally requested

The process of getting a sales licence from Health Canada is onerous, according to Durkacz. After receiving a cultivation license, a grower must produce two full crops, send them off for testing, get its sales software audited, and then submit a completed application for the sales licence, which can take up to 341 days to process, he said.

“So even after you’ve done everything and done everything right you could be waiting up to a year to get the licence,” he said.

Customers lineup at a government cannabis store Oct. 19, in Montreal on the third day of the legal cannabis sales in Canada. Canadian Press/Ryan RemiorzCanada became the first major economy to legalize recreational cannabis on Oct. 17, taking the lead in a global market that’s expected to reach US$32 billion in consumer spending by 2022, according to Arcview Market Research and BDS Analytics. The euphoria that sent pot stocks soaring in the lead-up to legalization has faded, with the BI Canada Cannabis Competitive Peers index losing 26 per cent over seven sessions before rebounding on Thursday.

While some growers wait for their licences, others are struggling to keep up with demand. The government-run Ontario Cannabis Store received 100,000 orders in its first 24 hours. In Quebec, online and in-store orders totalled nearly 140,000 in the first week of legalization, and the provincial-owned retailer indicated Wednesday it may have to close some locations as producers couldn’t meet demand. Producers will have a “colossal” amount of work to do to ensure supply, the Societe Quebecoise du Cannabis said in a statement.

A man holds a bag of marijuana he bought in a cannabis store in Quebec City, on Oct. 17. Alice Chiche/AFP/Getty ImagesThe problem is that no one knew what the demand curve would look like after a century of prohibition, said Bruce Linton, chief executive officer of Canopy Growth Corp., which has secured more than a third of total Canadian supply committed to date.

Canopy shipped approximately 1 million orders of medical cannabis in its first four years of operations. It expects to ship more than 1 million units of recreational pot in the first four weeks after legalization, Linton said.

‘Just Outstanding’

“The response has been pretty unbelievable,” Linton said. “I don’t think everything will run out but you might not be able to get the identical stuff you got last time.”

He added that Canopy is sending out orders as fast as it can pack and ship them, but there have been delays in getting new product up on the provincial websites. It will start shipping out new products, including Tweed-brand gel caps and pre-rolled joints, over the next week and a half.

Bruce Linton (left), Canopy Growth CEO, in St. Johns, Newfoundland sells the first gram of legal pot at the Tweed store at the stroke of midnight Oct. 17. Julie Oliver/PostmediaInitial demand at Alberta Gaming, Liquor and Cannabis was “just outstanding,” said Chara Goodings, a spokeswoman for the government regulator that’s overseeing sales in the western province. “But it has created some struggles with our supply level.” Very few producers have been able to deliver what was agreed upon, she said.

Dried Bud

The situation is similar in Manitoba, where Winnipeg-based Delta 9 Cannabis Inc. only has dried bud on its store shelves as it has been unable to get any shipments of cannabis oils or gel caps, said spokesman Gary Symons. In the first seven days, Delta 9 saw close to 9,600 transactions totalling $736,124 in revenues. The company is now selling about $50,000 worth of product a day.

“Every province, not just Manitoba, is receiving less cannabis than originally requested,” Susan Harrison, spokeswoman for Manitoba Liquor & Lotteries, said in an email.

Aphria Inc. CEO Vic Neufeld predicted the supply shortages on the company’s earnings call five days before legalization. Citing supply-chain issues, labor shortages and delays in getting licences and excise stamps from the government, Neufeld said Aphria would be unable to meet demand in the first two to three months after legalization. The company was forced to destroy almost 14,000 plants worth $979,000 in the last quarter due to a lack of qualified greenhouse workers.

Extra Staff

There are currently 132 licensed producers in Canada and “many more are in the queue,” said Canadian Health Minister Ginette Petitpas Taylor. Health Canada has hired 300 additional staff to evaluate applications, she said. But the process, which includes background checks, is time-consuming and it’s important to not cut corners, she said.

“There’s not a mass shortage of cannabis around the country right now,” only certain strains that have sold out, Petitpas Taylor said. “We really have all hands on deck, we want to do what we can, but in no way am I going to compromise this new regime.”

The challenge for the government is balancing public safety with a desire to eradicate the illicit market, said Deepak Anand, vice president of business development and government relations at Cannabis Compliance Inc., a consulting firm for pot companies which is currently working on “hundreds” of licensing applications.

“Health Canada’s trying to balance quality and public safety with the need for getting more product on so that they can eliminate the black market,” Anand said. “Sometimes these goals conflict and compete with each other.”

The only near-term solution to the supply shortage, according to Durkacz at FSD Pharma, is to allow retailers to sell product sourced from the black market.

“You would instantaneously have a supply-demand balance and then you could try to convert people from the black market to the legalized market,” he said. “That’s probably the only way to solve this in the short term.”

Source: https://business.financialpost.com/cannabis/cannabis-business/marijuana-shortages-abound-in-canada-amid-licensing-rigmarole

Demand for #marijuana real estate ‘astronomical’ as Canada legalizes $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:32 AM on Wednesday, October 24th, 2018
  • Demand for marijuana facilities, including greenhouses, indoor grow-ops and warehouses will put more demand on the country’s already tight supply of industrial real estate.
  • British Columbia and Ontario combined took up more than half of the existing grow-op space, Altus said.

The rush for cannabis is on in Canada and so is finding the real estate to grow it.

The legalization of recreational weed on Wednesday has already fuelled a sixfold surge in pot-growing facilities to 8.7 million square feet (808,256 square meters) in the year through September, according to data from Altus Group Ltd. — space about the size of Amazon.com Inc.’s Seattle headquarters. Publicly listed companies have another 6.4 million square feet on the drawing board, not including retail.

“It’s grown astronomically,” Raymond Wong, vice president of data operations at Toronto-based Altus, said by phone. “With the publicly traded companies, there’s a lot more investment in these areas with anticipated growth and available capital, and they’re acquiring and expanding their existing facilities.”

The demand for marijuana facilities, including greenhouses, indoor grow-ops and warehouses will put more demand on the country’s already tight supply of industrial real estate. British Columbia and Ontario combined took up more than half of the existing grow-op space, Altus said.

Wong said expansion plans are likely conservative as it excludes private companies’ anticipated growth. “There’s a whole other market out there that anticipates further growth in this area,” he said. “We don’t see this slowing down.”

Source: https://business.financialpost.com/real-estate/property-post/demand-for-pot-grow-ops-is-astronomical-as-canada-legalizes

Tetra Bio-Pharma $TBP.ca Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, October 24th, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
  • Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market

ORLEANS, Ontario, Oct. 24, 2018 РTetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Gigu̬re to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.

Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for several pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Over the past 10 years, he served as a member of the Board of Directors of the companies for which he worked.

“Richard has demonstrated his ability as a company builder which will prove crucial in his role as Chief Executive Officer of Tetra Natural Health,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc.  “He has begun preparing Tetra Natural Health as a wholly owned subsidiary of Tetra Bio-Pharma with the intentions of creating a market leader in the wellness sector of the cannabis market.”

“I am honored by this appointment as well by the confidence that Tetra Bio-Pharma has shown in me,” said Richard Giguère, CEO of Tetra Natural Health Inc. “As the CEO of Tetra Natural Health, I am excited and deeply committed to lead the operations of Tetra Natural Health with my colleagues through the next stages of development and success. Tetra has a sound business model, and there are several significant opportunities for Tetra Natural Health to grow and commercialize innovative natural health products. I am committed to exploiting the development of this huge potential market in the natural health sector.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Canada Running Short Of #Marijuana After Legalization $BOG.ca $NBUD.a $MCOA $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:54 AM on Monday, October 22nd, 2018

  • Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity
  • Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Oct 22, 2018 06:47 PM

The United States might be in for the same surprise when it legalizes the use of recreational marijuana or cannabis in the future.

Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity. Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Under the new law, Canadian citizens will be allowed to carry up to 30 grams of cannabis in public and each household will be able to grow up to four marijuana plants.

Statistics Canada, the country’s national statistics agency, estimated that 5.4 million Canadians will buy cannabis from legal dispensaries in 2018. That’s about 15 percent of the population. In addition, some 4.9 million Canadians already smoke weed. These projections included a boost from legalization but were still off the mark due to the high demand for cannabis.

Bill Blair, who led the government’s cannabis legalization program, said the country is unable to supply enough to meet demand. He said the government expected “certain strains might run out and there would be a bit of a run on supply.”

Cannabis supply began running low on Oct. 19. The supply dearth saw retailers are turning people away because they’d run out of stock.

The Ontario Cannabis Retail Corporation, the sole legal retailer of recreational cannabis in the province of Ontario, said some cannabis items are unavailable on its website. It said given the scarcity of cannabis products across Canada, it expects “significant” short-term supply problems.

Cannabis retailers in Alberta and Prince Edward Island said certain cannabis products quickly sold out online after vigorous business on their cannabis sales websites on the first day of legalization. Experts said the supply shortage situation is the same across Canada.

Experts said the shortage of cannabis brings with it the risk Canada might soon run out of practically its entire inventory of cannabis products. The situation is due to supply and demand with many users stocking-up due to worries there might not be enough stock in the stores over the next few weeks.

Cannabis demand is under threat because supply didn’t ramp up to meet demand, said marijuana advocate Steven Stairs. He expects the government to step in and try to ensure supply by mitigating regulation and taxation.

The Cannabis Commerce Association of Canada said most of the cannabis produced in Canada right now doesn’t come from the black market but rather from medically licensed growers, or the grey market. These licensed growers weren’t able to ramp-up production in time to meet demand because weed wasn’t legal at the time so there was no sense in boosting production.

Growers also held off on planting more weed because licenses allowing them to do so weren’t available before Oct. 17. Those who applied on Oct. 17 are still waiting for their applications to be processed.

Source: http://en.businesstimes.cn/articles/104225/20181022/canada-running-short-marijuana-legalization.htm

Marijuana Company of America $MCOA Applies for Uplisting to OTCQB and Finalizes S1 Registration Statement for Anticipated Equity Financing; Announces New Independent Director and Chief Financial Officer $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:00 AM on Thursday, October 11th, 2018

15233 mcoa

  • Announced that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets
  • Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million.

Escondido, California–(October 11, 2018) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets.

Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million. The Company’s application to uplist to the OTCQB tier is a condition for both the equity line of financing and for the Form S-1 registration statement.

Donald Steinberg, MCOA President and CEO commented: “Our goal is to obtain the necessary capital through our S1 to capitalize on the host of opportunities available in the cannabis and hemp industry right now. Also, moving to a higher OTC Markets reporting tier will help to provide better access to institutional investors, broaden our shareholder base, and provide greater credibility with the Company’s partners, clients, stakeholders, and customers, as well as with the wider investment community.”

The OTCQB tier increases transparency, reporting standards, management certification and compliance requirements. Further, the majority of broker dealers trade stocks on the OTCQB and historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

On August 31, 2018, the Company engaged Mr. Jesus Quintero as its new Chief Financial Officer, and on September 19, 2018, appointed Robert Coale as an independent director.

Mr. Quintero has served as a financial consultant to several multi-million dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance, and held senior finance positions with Avnet, Inc., Latin Node, Inc., Globetel Communications Corp. and Telefonica of Spain. His prior experience also includes tenure with Price Waterhouse and Deloitte & Touche. Mr. Quintero earned a B.S. in Accounting from St. John’s University and is a certified public accountant.

Mr. Coale brings years of experience in business consulting, private equity investments, financial and strategic joint venture facilitation, including telecommunications, banking, fund raising, non-profit, retirement, entertainment, licensing, gateway interface/merchant processing, real estate development, and strategic planning. Mr. Coale holds a Master’s in Business Administration, with an emphasis on International Marketing and Strategic Planning from Pepperdine University awarded in 1992; a Bachelor of Science with an emphasis in Finance from the University of Southern California awarded in 1982.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com

hempSMART.com

NetworkNewsWires/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Food and Drug Administration #FDA confirms nonclinical and manufacturing requirements #Tetra $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:56 AM on Thursday, October 11th, 2018

Logo tetrabiopharma rgb web

  • Received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product
  • Meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable
  • The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002

ORLEANS, Ontario, Oct. 11, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product.   The meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable.

The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002.  The FDA also provided feedback on the chemistry and manufacturing aspects of the drug development plan.  The FDA further confirmed that the product control strategy, ensuring the identity, potency, purity and quality of the PPP002 buccal tablets was acceptable thereby determining that Tetra Bio-Pharma’s plan is on track for drug approval.

“We have now completed our meetings with the U.S. FDA and Tetra is well on its way to finalizing the development plan to bring PPP002 to market,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. “With both the Type B and C meetings now behind us, we are able to move forward with executing the clinical program for PPP002 and subsequently submit the New Drug Application to commercialize PPP002.”

Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. These are the same indications that have already been approved for Marinol®.  The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. Tetra is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.

According to the International Agency for Research on Cancer, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US $1.88 billion by 2020, an increase from its 2013 valuation of US$1.28 billion. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ can gain significant market share within three years of its launch in the USA.

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP002, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Harvest Underway At #Marijuana Company Of America’s $MCOA #CBD Hemp Operation In Scio, Oregon $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:40 AM on Tuesday, October 2nd, 2018

15233 mcoa

  • Harvest has begun at the farm
  • Over the next 10 days the team in Scio will harvest this year’s crop, which consists of approximately 36,000 high yielding CBD hemp plants that were grown in an orchard style cultivation on 33 acres

ESCONDIDO, Calif., Oct. 02, 2018  – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG/ OTC: GBHPF/ FRANKFURT: GHG) (the “Partners”) are pleased to provide an update on their high yielding CBD hemp project in Scio, Oregon.

Harvest
Harvest has begun at the farm. Over the next 10 days the team in Scio will harvest this year’s crop, which consists of approximately 36,000 high yielding CBD hemp plants that were grown in an orchard style cultivation on 33 acres. The team planted six different cultivars this year to determine which would be the optimal hemp variety to grow in the coming year. The team continues to evaluate hemp cultivars that will provide higher CBD yields and a reduced flowering period, which will allow the team to complete the harvest earlier in the year prior to the fall rains.

Preparation for Extraction
Once the hemp is harvested, it will be dried in preparation for storage prior to processing. Drying this season will take place in the project’s four recently completed greenhouses on the farm and will utilize a traditional hanging method, as well as testing an innovative rack drying system. Prior to next season’s harvest, the Partners will construct a permanent drying facility on site. Once the hemp is dried to a 10-12% moisture content, it can be stored with little or no cannabinoid/plant matter degradation, prior to extraction.

Greenhouses
The team has now completed the setup of the first four of five greenhouses, giving the project 15,000+ sq. ft. of active greenhouse space for its drying and cloning operations. A fifth greenhouse (already purchased) will be installed after the drying of this year’s crop is complete. This will increase the active greenhouse space at the project to over 19,000 sq. ft. An additional 20,000 sq. ft. of greenhouse space will be purchased in October as part of further project expansion, with the vision of implementing a year round perpetual harvest model to enhance revenue generation and cash flow, and increasing the size of the cloning operation to be able to supply clones to the local farming community.

The team has now started its cloning operations for the winter crop, which will utilize the current and future greenhouses. Management is exploring opportunities to maximize production by developing beneficial relationships that will help optimize the Project’s profit potential through R&D, data collection and analysis.

Discussions with local Farmers
With the success of this year’s hemp cultivation on display at the farm, it has attracted the attention of the local community and many local farmers that are interested in growing hemp as hemp generates a far greater Return On Investment per acre than any other crop they are currently growing. The Project’s stated goal has been to use 2018 as an initial commercial trial and then to significantly expand the acreage under cultivation in the coming years. Management is currently in discussions with a number of these local farmers regarding contract farming and share cropping for the project, starting next year.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG), is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The Company is headquartered in Vancouver, British Columbia, with hemp cultivation operations in New Brunswick and Oregon. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/91c6e0d5-8f9a-4b46-a157-e7d6f6567932
http://www.globenewswire.com/NewsRoom/AttachmentNg/2e31feb6-b422-485b-bef9-7972db707e8c